Type of information: Loan
Company: Abivax (France)
Investors: Bpifrance (France) Région Occitanie /Pyrénées-Méditerranée (France)
Funding type: loan
- • The loan will be used to develop of a cocktail of polyclonal antibodies against the Ebola virus. Abivax's Ebola program (ABX544 is targeting the development of specific polyclonal rabbit antibodies directed against the Ebola virus glycoprotein. This loan specifically covers the implementation of production and purification processes for the glycoproteinand for the specific IgG from immunized rabbits, as well as proof of concept studies in vitro and in vivo.
ABX544 program targets the generation of an Ebola hyperimmune serum, containing
neutralising antibodies produced from animals immunised with a specific Ebola antigen. ABX544 is expected to have an immediate effect when administered. It can be applied either as treatment of infected persons or for protection
of non-infected persons including health care workers, constituting a first line of defence during epidemic outbreaks. Following the formal preclinical evaluation including toxicology, Abivax aims to bring ABX544 into clinical trials.
- • On June 12, 2017, Abivax announced that Bpifrance and
Région Occitanie /Pyrénées-Méditerranée have agreed to provide a loan of €390,000 to the company for the development of a cocktail of polyclonal antibodies against the Ebola virus.
Therapeutic area: Infectious diseases